Fragmenting ions and radiation sensitizers

September 03, 2019

A new study using mass spectrometry is helping piece together what happens when DNA that has been sensitized by the oncology drug 5-fluorouracil is subjected to the ionising radiation used in radiotherapy.

The anti-cancer drug 5-fluorouracil (5FU) acts as a radiosensitizer: it is rapidly taken up into the DNA of cancer cells, making the cells more sensitive to radiotherapy. However, little is known about the precise mechanism through which radiation damages cells. A team of scientists led by Peter van der Burgt at the National University of Ireland in Maynooth, Ireland have now used mass spectrometry to shed some light on this process; their work was recently published in EPJ D. A full understanding of this process could ultimately lead to new ways of protecting normal tissues from the radiation damage caused by essential cancer treatments.

Radiotherapy involves delivering radiation, in the form of X-rays, to the cancer site. The X-rays or other high-energy particles collide with the molecules they encounter, knocking off electrons to form positively-charged ions, and these ions and electrons in turn react with other molecules in the cells: this can kill cancer cells, but can also cause short- and long-term damage to others.

5-fluorouracil resembles the bases in normal DNA but is more sensitive to radiation, both on its own and when incorporated into DNA. Van der Burgt and his colleagues investigated this sensitivity by producing a stream of 5FU particles in a mass spectrometer and colliding them with a beam of radiation. The spectrometer was then used to determine which ions were formed in the collisions by measuring their mass-to-charge ratio. Two sets of experiments were carried out: one using electrons as the radiation source, and the other using high-intensity photons.

Increasing the energy of the radiation increased the number and type of ions that were formed; the researchers identified many different fragment ions and determined the radiation level at which each was first formed. These included some ions that were absent from the spectrum of the natural base, uracil, and some that had not been observed in this type of experiment before. Undoubtedly, similar processes take place in the tissues of patients undergoing radiotherapy.
-end-
Reference:

P.J.M. van der Burgt, M.A. Brown, J. Bockova, A. Rebelo, M. Ryszka, J-C. Poully and S. Eden (2019) Fragmentation processes of ionized 5-fluorouracil in the gas phase and within clusters, European Physical Journal D 73: 184, DOI: 10.1140/epjd/e2019-100107-7

Contact:

Sabine Lehr
Springer Physics Editorial
Tel: +49-6221-4487-8336
Email: sabine.lehr@springer.com

Springer

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.